Sporadic mutations in the gene for the transcription factor CCAAT-enhancer-binding protein a (CEBPA) occur in approximately 7-9% of patients with acute myeloid leukemia (AML). 1 Most of these patients harbor biallelic mutations, consisting of an N-terminal and a C-terminal mutation, which lead to loss of function of CEBPA and cause a differentiation block in the leukemic blasts.
In this study, we describe a family with AML revealing a N-terminal 338delC CEBPA germline mutation (referenced to GenBank accession number Y11525, Figures 1 and 2 ). The 30-year-old mother had a history of acute lymphoblastic leukemia, remaining in complete remission (CR) for more than 25 years, when she was diagnosed with AML French-AmericanBritish type M2 with normal karyotype. She was treated with two cycles of induction chemotherapy (idarubicin, cytarabine and etoposide) and one cycle of high-dose cytarabine and mitoxantrone. After 15 months of CR, a relapse of the AML with normal karyotype occurred. When tested for molecular aberrations, a 338delC CEBPA germline mutation and an additional acquired C-terminal 1085insGAA mutation were detected (the germline mutation was verified by additional analyses of buccal mucosa). Both mutations were also present in samples from the initial diagnosis of AML, which were obtained within a prospective clinical trial. The patient's parents and her sister were tested negative for CEBPA germline mutations, and the family history showed no evidence of an inherited predisposition to hematological cancer ( Figure 1 ). The patient was treated with chemotherapy (fludarabine and cytarabine) and achieved a second CR. Subsequently, she received an allogeneic hematopoietic stem cell transplantation from a matched unrelated donor (10 out of 10 human leukocyte antigens loci matched; intermediate resolution DNA typing for human leukocyte antigens-A, -B and -Cw, and high-resolution DNA typing for DRB1 and DQB1). Due to intense pre-treatment and treatmentrelated congestive heart failure, a dose-reduced conditioning regimen was chosen consisting of 120 mg/m 2 fludarabine (given on 3 consecutive days) and 8 Gy total body irradiation (divided in 4 fractions over 2 days). Acute graft-versus-host disease prophylaxis consisted of anti-thymocyte globuline, cyclosporine A and a short course of methotrexate. Unfortunately, the patient died from unexpected sudden cardiac death 18 months after transplant. At that time, the patient was in continuous CR with complete donor chimerism of hematopoietic cells and no signs of graft-versus-host disease. Figure 2 Schematic representation of the wild-type CCAAT-enhancerbinding protein a (CEBPA) and the projected mutant forms in the mother and daughter as described. Both patients had a germline mutation in the 5 0 region of the coding sequence, which results in an N-terminal mutant of CEBPA. N-terminal mutants have been described to exert dominant negative activity over wild-type CEBPA.
1 Both patients also harbor a C-terminal mutation that presumably results in altered heterodimerization and DNA binding of the mutant protein.
Interestingly, the C-terminal mutants were different but very similar in the leukemic cells from the mother and those from the daughter. different gene loci of maternal DNA and of DNA from AML blasts, excluded maternal origin of the leukemia. In addition to the germline 338delC CEBPA mutation, a C-terminal duplication of bases 1072-1083 of the CEBPA-coding sequence was detected in the leukemic blasts. The father was tested negative for CEBPA mutations. The daughter received induction chemotherapy with cytarabine, liposomal daunorubicine and etoposide. Early bone marrow evaluation 15 days after first induction therapy showed persistent disease. After a second course of induction therapy with high-dose cytarabine and mitoxantrone and an additional course with fludarabine and cytarabine and granulocyte-colony-stimulating factor, the patient achieved a CR. Due to the high risk of relapse after induction failure, an allogeneic hematopoietic stem cell transplantation in first remission was scheduled. 2 The patient received two courses of consolidation therapy (fludarabine and cytarabine; high-dose cytarabine and mitoxantrone) and a conditioning therapy consisting of 19.2 mg/kg busulfan (given i.v. on 4 consecutive days) and 120 mg/kg cyclophosphamide (given on 2 consecutive days). She was transplanted with peripheral blood stem cells from a matched unrelated donor (10 out of 10 human leukocyte antigens loci matched; high-resolution DNA typing for human leukocyte antigens-A, -B, -Cw, -DRB1 and -DQB1) and received anti-thymocyte globuline and cyclosporine A as graft-versus-host disease prophylaxis. 5 years after transplant the patient is in continuous CR, with complete donor chimerism of hematopoietic cells and no evidence for graft-versus-host disease.
Mutations in the genes of hematopoietic transcription factors or oncogenes are increasingly studied and detected in patients with AML. In the case of CEBPA, biallelic mutations are often found that lead to a loss of function below a critical threshold. 3 There have been several reports of familial AML with CEBPA germline mutations. [4] [5] [6] [7] Two siblings with AML and their father with a history of AML harboring a germline 212delC N-terminal CEBPA mutation were described. Additionally, an acquired 36-bp C-terminal CEBPA gene duplication at nucleotides 1050-1085 was found in one of the siblings at the time of leukemia. 4 In a second report, five individuals with familial AML harboring a germline 217insC mutation were presented. Two individuals had an additional C-terminal mutation at nucleotide 1071 (two different insertions). 5 In two larger series of patients with CEBPA mutations, the frequency of germline CEBPA mutations was found to be around 7-11%. 6, 7 As in the previously reported cases, both affected family members in the family described in this study had the identical germline N-terminal but different somatic C-terminal CEBPA gene mutation. The 338delC results in a truncated CEBPA protein due to a frameshift with a premature stop codon at nucleotide 623. The C-terminal mutations are predicted to disrupt dimerization and consequently lead to loss of DNA-binding activity. No NPM1 mutation or FLT3 internal tandem duplication were found in the mother and the daughter. These findings are in line with recent reports suggesting that CEBPA germline mutations predispose to the development of leukemia, and that in these cases the second mutational 'hit' is an acquired mutation in the remaining CEBPA allele. In our patient's relapsed disease and the delayed response to chemotherapy prompted us to perform an allogeneic transplantation. We reasoned that this might also replace the hematopoietic stem cells carrying the germline CEBPA mutation and thus to minimize the risk of relapse. As in the case reported by Sellick et al., 5, 8 there is evidence for anticipation in the present cases. It is intriguing to speculate that the length of triple nucleotide insertions may have had a role similar to what has been postulated by Horwitz et al. 9 In our family, the somatic mutation detected in the maternal DNA was a 3-base insertion, whereas the daughter presented with a 12-base duplication. Although anticipation is generally associated with paternal inheritance, the germline mutation was passed on by the mother in our current report. Because of the high incidence of somatic C-terminal mutations (5 of 6 evaluable cases ¼ 83% as compared with 7-9% of sporadic cases 1 ) and the high frequency of relapses in the previous cases, 4, 5 we propose that transplantation should be considered in AML, with CEBPA germline mutations as a means to replace the mutated hematopoietic stem cells and eliminate the risk of subsequent C-terminal somatic mutations and relapse in these patients.
For three of the four adult AML patients with CEBPA germline and somatic mutation in the second allele recently published by Taskesen et al., 7 further data on clinical outcome are available. All three patients (including our adult patient) relapsed after standard induction and consolidation therapy, and received an allogeneic transplant. Two of these patients died in second CR and one is alive in CR.
